国际皮肤性病学杂志    2003 29 (3): 138-140   ISSN: 2096-5540  CN: 32-1880/R   系统性硬皮病治疗的研究进展 雷霞, 伍津津 第三军医大学大坪医院野战外科研究所皮肤科, 重庆400042 收稿日期 2002-07-12  修回日期 null  网络版发布日期 null 参考文献  [1] White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am, 1996, 22(4):695-708. [2] Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am, 1996, 22(4):647-674. [3] Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma:clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum, 1999, 42(12):2646-2655. [4] Black CM, Halkier-Sorensen L, Belch JJ, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis:a multicentre,placebo-controlled, dose-comparison study. Br J Rheumatol, 1998,37(9):952-960. [5] Leighton C. Drug treatment of scleroderma. Drugs, 2001, 61 (3):419-427. [6] Furst DE, Clements PJ, Hillis S, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a threeyear, parallel, randomized, double-blind study. Arthritis Rheum,1989, 32(5):584-593. [7] van den Hoogen FH, Boerbooms AM, Swaak A J, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis:a 24week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol, 1996, 35(4):364-372. [8] Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum, 1993, 36(1):75-83. [9] Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, et al. The impact of pain and symptoms of depression in scleroderma. Pain, 2002,95(3):267-275. [10] Medsger TA Jr, Lucas M, Wildy KS, et al. D-penicillamine in systemic sclerosis? Yes! Scand J Rheumatol, 2001, 30(4):192-194. [11] Wigley FM, Sule SD. Novel therapy in the treatment of scleroderma.Expert Opin Investig Drugs, 2001, 10(1):31-48. [12] Ben-Chetrit E, Levy M. Colchicine:1998 update. Semin Arthritis Rheum, 1998, 28(1):48-59. [13] Denton CP, Black CM. Novel therapeutic strategies in scleroderma.Curr Rheumatol Rep, 1999, I(1):22-27. [14] Le CH, Morales A, Trentham DE. Minocycline in early diffuse scleroderma. Lancet, 1998, 352(9142):1755-1756. [15] Simon JC, Pfieger D, Schopf E. Recent advances in phototherapy.Eur J Dermatol, 2000, 10(8):642-645. [16] Mayas MD. Photopheresis and autoimmune diseases. Rheum Dis Clin North Am, 2000, 26(1):75-81. [17] Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol, 2002, 138(1):99-105. [18] Bingham SJ, Snowden JA, Emery P. Autologous blood stem cell transplantation as therapy for autoimmune diseases. Ann Med, 2000,32(9):615-621. [19] Furst DE, Tyndall A. Stem cell transplantation in systemic sclerosis:rationale and status report. Isr Med Assoc J, 2000, 2 (12):935-937. [20] Ellman MH,MeDonald PA, Hayes FA, et al. Etanercept as treatment for diffuse scleroderma:a pilot study [abstract]. Arthritis Rheum,2000,43:S392. [21] Schachna L, Wigley FM, White B, et al. Lung transplantation in scleroderma:the Johns Hopkins experience [abstract]. Arthritis Rheum,2000,43:S392. [22] Kubo M, Vensak J, Dauber J, et al. Lung transplantation in patients with scleroderma. J Heart Lung Transplant, 2001, 20 (2):174-175. 通讯作者: